Cardiac toxic effects from paclitaxel with trastuzumab, presenting as grade 3 or 4 left ventricular systolic dysfunction (LVSD) or asymptomatic left ventricular ejection fraction decline (LVEF), were low in patients with node-negative, ERBB2-positive breast cancer, a new study published online ahead of print in JAMA Oncology has shown.
by Jason Hoffman, PharmD, RPh
Cancer Therapy Advisor
November 06, 2015
